Orthofix Medical - OFIX Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" OFIX shares.
View OFIX analyst ratings or view top-rated stocks.

1 analysts have issued 12 month price targets for Orthofix Medical's shares. Their OFIX share price forecasts range from $45.00 to $45.00. On average, they expect the company's share price to reach $45.00 in the next year. This suggests a possible upside of 125.2% from the stock's current price.
View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts.

Orthofix Medical's stock was trading at $31.09 at the beginning of the year. Since then, OFIX stock has decreased by 35.7% and is now trading at $19.98.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our OFIX earnings forecast.

Orthofix Medical Inc. (NASDAQ:OFIX) announced its quarterly earnings results on Friday, November, 5th. The medical device company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.13 by $0.03. The medical device company earned $112.43 million during the quarter, compared to analysts' expectations of $112.90 million. Orthofix Medical had a positive trailing twelve-month return on equity of 1.90% and a negative net margin of 8.00%. During the same period in the previous year, the company earned $0.31 EPS.

Orthofix Medical updated its FY 2022 earnings guidance on Friday, September, 2nd. The company provided earnings per share (EPS) guidance of $0.45-$0.55 for the period. The company issued revenue guidance of $455.00 million-$465.00 million, compared to the consensus revenue estimate of $479.18 million.

32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).

Orthofix Medical trades on the NASDAQ under the ticker symbol "OFIX."

Orthofix Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Paradice Investment Management LLC (4.80%), State Street Corp (3.92%), Renaissance Technologies LLC (2.76%), Victory Capital Management Inc. (1.26%), Northern Trust Corp (1.08%) and JPMorgan Chase & Co. (0.86%). Insiders that own company stock include Catherine M Burzik, James F Hinrichs, Jon Carl Serbousek, Kimberley A Elting, Michael E Paolucci, Rice Doug and Ronald A Matricaria.
View institutional ownership trends.

Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OFIX stock can currently be purchased for approximately $19.98.

Orthofix Medical (NASDAQ:OFIX) has a market capitalization of $397.80 million and generates $464.48 million in revenue each year. The medical device company earns $-38,380,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis.

The company employs 1,087 workers across the globe.

Orthofix Medical's mailing address is 3451 Plano Parkway, Lewisville TX, 75056. The official website for the company is www.orthofix.com. The medical device company can be reached via phone at (214) 937-2000, via email at markquick@orthofix.com, or via fax at 599 9 461 6978.